Monday, August 14, 2006Trade for 9 @ KodakKotak offers flat fee model for share deals Accorinding to Hindu Businessline Kodak offers trade at 9 INR. This is equal to a cup of coffee or tea in decent resturant. Even the higher end fee of 18 INR is dirty cheap. ICICI and other companies need to consider this and lower their rates to match this fee. There is another catch involved with Kodak, ie The 9 rupees fee is not flat, theres a 499 monthly fee and the 9 rupees is for every multiple of INR 5000. If you want a really flat structure it is at 20 rupees per trade without a monthly fee. So, its not as pathbreaking as it was made out to be in the initial report. Kotak Securities is offering investors the privilege of a flat fee for shares purchased by them, the company said here on Monday. Labelled `Kotak Flat', the fixed fee-based brokerage model is offered for its Internet-based traders and customers. "Internet-based trading has enormous potential in the country and it has grown to 12 per cent of the total trade as compared to just 2 per cent a couple of years ago. With an easy brokerage structure, we will be able to acquire a million customers online by the end of this year," said Mr S.A. Narayan, Managing Director, Kotak Securities, on the occasion of the launch of their new product. For all deliveries up to Rs 5,000 and non-deliveries up to Rs 50,000, the brokerage would be Rs 9 per deal (statutory charges extra). For deliveries exceeding Rs 5,000, investors will have to pay an additional Rs 9 for every transaction amounting to Rs 5,000. "This is the best bargain available for retail investors in India. The brokerage scheme will be three times cheaper than normal market brokerage norms. Moreover, `Kotak Flat' is applicable on all trades — delivery, square off and options/futures — and invests on both the NSE and BSE,'' said Mr Prasanth Prabhakaran, senior Vice-President, Kotak Securities. HDFC Securities has declined to comment, stating, "The company will have to see the product before making a comment.'' However, majority of the brokers see the launch as a pre-emptive measure to other stock broking firms offering a flat fee structure and thereby erode Kotak's market presence. "Many other firms are in the process of coming out with fixed brokerage models," said a senior market analyst of a leading brokerage. Brokers are of the opinion that `Kotak Flat' will cater only to a small class of investors. Top Gainers , Loosers and Volume toppers
Yo PICKNavin Fluorine International Ltd.(POLRUB) Navin Fluorine's profitability is slated to receive a major boost on the back of improving core business, retiring of de-merger liabilities and windfall gains from carbon credits. Improved financials are likely to percolate into higher returns for shareholders along with bolstering its core business. Demanding valuation along with impressive outlook is slated to drive the valuations northwards. We rate the stock an OUTPERFORMER with an upside potential to Rs 400 from a 9-12 months perspective. Bartronics India - Outcome of AGM
Bartronics India Ltd has informed that the members at the 15th Annual General Meeting (AGM) of the Company held on July 28, 2006, inter alia, have accorded to the following:
1. Adoption of the Balance Sheet as at March 31, 2006 and Profit and Loss Account for the year ended on that date as Audited and certified by the Company's Auditors together with the Report of Auditors dated June 10, 2006 and Report of Directors as on that date. 2. Re-appointment of Shri. R Satish Reddy as Director of the Company. 3. Re-appointment of M/s. Yaji Associates, Chartered Accountants, Hyderabad, as Auditors of the Company to hold office from the conclusion of this Annual General Meeting until the conclusion of the next Annual General Meeting of the Company on remuneration, terms and conditions. 4. Authority to the Board for borrowing from time to time all such sums of money as they may deem requisite for the purpose of the business of the Company notwithstanding that moneys to be borrowed together with moneys already borrowed by the Company (apart from temporary loans obtained from the Company's bankers in the ordinary course of business) up to a limit not exceeding in the aggregate of Rs 2500 million including Foreign borrowings like Foreign Currency Convertible Bonds, Foreign Currency Bonds etc. notwithstanding that moneys to be borrowed, together with the moneys already borrowed by the Company apart from temporary loans obtained from the Company's Bankers in the ordinary course of business will exceed the aggregate of the paid up Capital of the Company and its free reserves, that is to say, reserves not set apart for any specific purpose, subject to necessary provisions & approvals. 5. Increase in the remuneration payable to Shri. Sudhir Rao, Managing Director of the Company w.e.f. April 01, 2006. India Cements has target of Rs 210-215
Gujral told CNBC-TV18, "India Cements has found good support at around Rs 180. Cement will be a good performer post October, October-March is really the construction season in this country. One needs to hold on. First target would be at around Rs 210-215 and if the market remains good one will probably see upto even Rs 240-245."
Biocon an outperformer, target of Rs 415:The Karvy Stock Broking report on Biocon: Various Factors to sustain the revenue momentum "On the back of six month exclusivity granted to Pravastatin and Simvastatin we believe the full upside of the Statin upside would be pushed to FY2008E. We believe the company would have Statin revenues of Rs 3 billion in FY2007E which will increase to Rs 3.4 billion in FY 2008E. Contract Research services is expected to scale up from Rs 1.4 billion in FY 2007E to Rs 1.8 billion in FY 2008E on the back of continuous scale up in expansion of space. Continuous revenue momentum in Syngene and renewed traction in Clinigene will enable the company to show the revenue growth momentum. Insulin, Enzymes and Monoclonal Antibodies are also expected to contribute Margins expected to be on the upswing "Scale up in the regulated markets of US coupled with growth in the high margin Monoclonal antibodies segment, Insulin and the Contract Research services should give the company the requisite momentum to increase margins from 29% in FY2006 to 33.6% in FY2008. Savings in materials cost has more than offset the increase in power and personnel costs." Reasonable valuations and earnings growth make it outperformer "Biocon is currently quoting at 19x FY2007E (EPS Rs 18.5) and 13.3x FY2008E (EPS Rs 26). With statin supplies commencing from 2nd half, contract research business scaling up, tie up with Bayer for the Chinese Insulin market and announcement of European partnership for Insulins, updates on Oral Insulin progress and further progress on various other indications for the monoclonal antibodies apart from Head and Neck Cancer are the positive events to unfold in the future. We rate the stock as an outperformer with a price target of Rs 415 based on 16x FY 2008E." Prism Cement can test Rs 38-40Gaba told CNBC-TV18, "Prism Cement had given a beautiful breakout at Rs 30-31 levels. It had a target of Rs 35 and that is where it is today. We might see some kind of profit booking here. But I must say that the trend is still intact. It is in an upmode and as long as it stays above Rs 33 levels the next target would be around Rs 38-40 in time to come. The structure is positive, it is in an upmode. I must disclose that I have the stock in my portfolio." |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
